Bruker ( NASDAQ: BRKR ) has made a minority investment in Strasbourg, France-based contract research organization (CRO), NovAliX. Financial details of the investment were not disclosed. NovAliX is a drug discovery focused CRO with one of the world’s most comprehensive biophysics platforms.
Its scientific and technical workforce includes over 430 people, distributed across its European R&D and CRO service sites and an additional medicinal chemistry North-African site. Bruker’s ( BRKR ) investment aims to accelerate the growth and further expansion of NovAliX, particularly within Europe and the U.S.
The partnership will enable both companies to accelerate the development, incubation, deployment, and support for advanced biophysical methods. Anticipated areas of joint innovation in drug discovery methods include: ultra-high field NMR functional structural and binding investigations on protein and RNA structures and complexes, as well as on novel therapeutic peptides and oligonucleotides; NMR-powered medicinal chemistry, structure-activity relationships and MoA research; and biologics and new drug modalities higher-order structure confirmation, similarity assessment and QC by NMR, among others. More on Bruker Bruker: A Confusing Acquisition Spree Bruker beats top-line and bottom-line estimates; raises FY24 revenue outlook Bruker Q2 2024 Earnings Preview Seeking Alpha’s Quant Rating on Bruker Historical earnings data for Bruker.